Lack of effect of treatment for Helicobacter pylori on symptoms of nonulcer dyspepsia

Archives of Internal Medicine

Volumn 159, Issue 19, 1999, Pages 2283-2288

  Greenberg, Paul D ^a,b   Cello, John P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Merck Medco Managed Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; CLARITHROMYCIN; IMMUNOGLOBULIN G ANTIBODY; OMEPRAZOLE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSGEUSIA; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FOLLOW UP; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH BIOPSY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, BACTERIAL; BLOTTING, WESTERN; DYSPEPSIA; ENZYME INHIBITORS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT FAILURE;

EID: 0032713279     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.19.2283     Document Type: Article

References (34)

1. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology. 1992;102:1259-1268.
2. Silverstein MD, Petterson T, Talley NJ. Initial endoscopy or emprical therapy with or without testing for Helicobacter pylori for dyspepsia: a decision analysis. Gastroenterotogy. 1996;110:72-83.
3. Bytzer P, Hansen JM, Schaffalitzky de Muchadell O. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet. 1994;343: 811-816.
4. McCarthy C, Patchett S, Collins RM, Beattie S, Keane C, O'Morain C. Long-term prospective study of Helicobacter pyloriin nonulcer dyspepsia. Dig Dis Sci. 1995; 40:114-119.
5. Lazzaroni M, Bargiggia S, Sangaletti O, Maconi G, Boldorini M, Porro GB. Eradication of Helicobacter pylori and long-term outcome of functional dyspepsia. Dig Dis Sci. 1996;41:1589-1594.
6. Sheu BS, Lin CY, Lin XZ, Shiesh SC, Yang HB, Chen CY. Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: a prospective controlled assessment. Am J Gastroenterol. 1996;91:441-447.
7. Kang JY, Tay HH, Wee A, Guan R, Math MV, Yap I. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia: a double blind placebo controlled study. Gut. 1990;31:476-480.
8. Lambert JR, Dunn K, Borromea M, Korman MG, Hansky J. Campylobacter pylori: a role in non-ulcer dyspepsia? Scand J Gastroenterol. 1989;24:7-13.
9. Rokkas T, Pursey C, Uzoechina E, et al. Non-ulcer dyspepsia and short term DeNol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori. Gut. 1988;29:1386-1391.
10. McNulty C, Gearty JC, Crump B, et al. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. BMJ. 1986;293:645-649.
11. Bernersen B, Johnsen R, Bostad L, Straume B, Sommer AI, Burhol PG. Is Helicobacter pylori the cause of dyspepsia? BMJ. 1992;304:1276-1279.
12. Elta GH, Scheiman JM, Barnett JL, et al. Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients. Am J Gastroenterol. 1995;90: 1089-1093.
13. Loffeld RJLF, Potters HVJP, Stobberingh E, Flendrig JA, Van Spreeuwel JP, Arends JW. Campylobacter-associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate. Gut. 1989; 30:1206-1212.
14. Marshall BJ, Valenzuela JE, McCallum RW, et al. Bismuth subsalicylate suppression of Helicobactsr pylori in nonulcer dyspepsia: a double-blind placebo-controlled trial. Dig Dis Sci. 1993;38:1674-1680.
15. Glupczynski Y, Burette A, Labbe M, Deprez C, De Reuck M, Deltenre M. Campyiobacter pylori associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol. 1988;83:365-372.
16. Patchett S, Beattie S, Leen E, Keane C, O'Morain C. Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia. BMJ. 1991;303:1238-1240.
17. Frazzoni M, Lonardo A, Grisendi A, et al. Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? a diagnostic and therapeutic study. J Clin Gastroenterol. 1993;17:101-108.
18. Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology. 1994;106:1174-1183.
19. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, et al. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol. 1996;91:660-673.
20. American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 1998;114:579-595.
21. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on long-term recurrence of gastric or duodenal ulcer. Ann Intern Med. 1992;116:705-708.
22. Sung, JJ, Chung SS, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med. 1995;332:139-142.
23. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308-312.
24. Forbes GM, Glaser ME, Cullen DJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994;343:258-260.
25. Santander C, Gravalos RG, Gomez-Cedenilla A, Cantero J, Pajares JM. Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. Am J Gastroenterol. 1996; 91:1549-1552.
26. Soil AH. Medical treatment of peptic ulcer disease. JAMA. 1996;275:622-629.
27. Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal anti-inflammatory agents. Am J Med. 1984; 77:19-24.
28. Dawson-Saunders B, Trapp RG. Basic and Clinical Biostatistics. 2nd ed. East Norwalk, Conn: Appleton & Lange; 1994.
29. Walsh JH, Peterson WL The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995;333:964-991.
30. Camilleri M. Nonulcer dyspepsia: a look into the future. Mayo Clin Proc. 1996; 71:614-622.
31. Ofman JJ, Etchason J, Fullerton S, Kahn KL, Soll AH. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med. 1997;126:280-291.
32. Bytzer P. Diagnosing dyspepsia: any controversies left? Gastroenterology. 1996; 110:302-306.
33. NIH Consensus Development Panel on Helicobacter pylori m Peptic Ulcer Disease. NIH Consensus Conference: Helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65-69.
34. Talley NJ, Weaver AL, Tesmer DL, Zinmeister AR. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology. 1993;105:1378-1386.